Search

Search Constraints

You searched for: Author/Creator Armstrong, Deborah K

Search Results

1. 2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types. (20th October 2022)

2. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Issue 6 (June 2017)

4. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2020)

5. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10106 (28th October 2017)

6. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Issue 7 (8th June 2021)

7. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression‐free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Issue 7 (July 2021)